- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canopy Growth Statement Regarding Possible Class Action Related to Mettrum Health Recall
Canopy Growth (TSX:WEED) published a response regarding a possible class action suit that has named newly-acquired Mettrum Health. As quoted in the press release: Details of a possible class action suit naming Mettrum Health Corp., an entity that was fully acquired by Canopy Growth Corporation (“Canopy Growth” or “the Company”) (TSX: WEED) on January 31, 2017 have …
Canopy Growth (TSX:WEED) published a response regarding a possible class action suit that has named newly-acquired Mettrum Health.
As quoted in the press release:
Details of a possible class action suit naming Mettrum Health Corp., an entity that was fully acquired by Canopy Growth Corporation (“Canopy Growth” or “the Company”) (TSX: WEED) on January 31, 2017 have been publicly reported.
In response to these reports, the Company wishes to state that it conducted thorough due diligence during the process of acquiring Mettrum Health Corp. and was aware of the extent and scope of the recall Mettrum was conducting.
Canopy Growth was, and continues to be satisfied with Health Canada’s independent decision to classify the Mettrum recall as a Type III recall, defined as “a situation in which the use of, or exposure to, a product is not likely to cause any adverse health consequences.”
The Company will defend itself vigorously against all suits relating to Mettrum recalls.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.